2022 Angiotensin GRC/GRS

2022 血管紧张素 GRC/GRS

• 批准号: 10381797
• 负责人: Minolfa C Prieto
• 金额: $ 4万
• 依托单位: GORDON RESEARCH CONFERENCES
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-11-23 至 2022-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10381797
• 关键词: 2019-nCoV; ACE2; Academia; Address; Adipose tissue; Aging; Angiotensin I; Angiotensin II; Angiotensin Receptor; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Anniversary; Area; Award; Basic Science; Biology; Blood Pressure; Bone Marrow; COVID-19; COVID-19 pandemic; Cardiometabolic Disease; Cardiovascular Diseases; Cardiovascular Physiology; Cardiovascular system; Clinic; Clinical; Clinical Medicine; Clinical Sciences; Collaborations; Data; Development; Diabetes Mellitus; Digestive System Disorders; Disease; Doctor of Medicine; Doctor of Philosophy; Electrolyte Balance; Electrolytes; Endocrine System Diseases; Enzymes; Etiology; Event; Fostering; Funding; Future; Gender; Generations; Goals; Health; Health Sciences; Hematological Disease; Homeostasis; Human Biology; Hypertension; Immune response; Immune system; Industry; Inflammatory Response; Institutes; International; Joints; Kidney; Kidney Diseases; Lead; Leadership; Life Cycle Stages; Liquid substance; Mediator of activation protein; Medical Research; Mentors; Mentorship; Metabolic Diseases; Minority Groups; Mission; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Disease; National Institute of Diabetes and Digestive and Kidney Diseases; Neurocognition; Neurosecretory Systems; Nutrition Disorders; Obesity; Organ; Outcome; Oxidative Stress; Pathologic Processes; Pathology; Persons; Pharmacogenomics; Population; Postdoctoral Fellow; Productivity; Proteins; Proteomics; Public Health; Quality of life; Regulation; Renin-Angiotensin-Aldosterone System; Research; Research Personnel; Research Training; Role; SARS-CoV-2 infection; Science; Scientist; Sex Differences; System; Therapeutic; Tissues; Translating; Translational Research; Travel; Underrepresented Minority; Underrepresented Populations; United Kingdom; United States National Institutes of Health; Universities; Urologic Diseases; Virginia; Woman; Women Physicians; angiotensin I (1-7); arm; base; career; career development; design; fetal programming; frontier; graduate student; human disease; improved; insight; liver function; meetings; metabolomics; minority student; nephrogenesis; novel; precision medicine; programs; receptor; receptor function; success; symposium; systems research; therapeutic target; tool; undergraduate student

PROJECT SUMMARY The renin angiotensin aldosterone system (RAAS) is a key regulator of cardiovascular (CV) function, fluid electrolyte balance, and homeostasis, and it influences many systems including the renal, neuroendocrine, and immune systems. Perturbations of the RAAS trigger a cascade of events, including generation of vasoactive mediators, oxidative stress, inflammatory responses, and tissue remodeling, thus contributing to end-organ pathology and disease. In the 2022 GRC on Ang, we will discuss the most recent, cutting-edge discoveries in the field and share insights on emerging new areas beyond the CV system such as the role of the RAAS in adipose biology, bone marrow regulation, liver function, neurocognition, and immune responses. The conference will focus on the latest advances of the RAAS from discovery science to clinical impact. A highlight in 2022 will be the celebration of 22 years of the discovery of ACE2. ACE2 is a multifunctional protein, that not only is CV protective by generating Ang-(1-7) and Ang-(1-9) from Ang II and Ang I respectively, but it is also, tissue injurious by acting as the receptor for the SARS-CoV-2, the etiologic agent of the current worldwide COVID-19 pandemic. The enigmas of ACE2 as a key enzyme in the protective arm of the RAAS will be a highlight. The role of ACE2 as a major mediator and potential therapeutic target in COVID-19 will be debated along with the controversies on the progression of COVID-19 infection and long-term outcomes in populations treated with ACE inhibitors and/or angiotensin receptor blockers. The 2022 GRC on Ang will further feature novel topics including sex-differences in the regulation and changes of the RAAS during the life course (fetal programming, kidney development, and aging) will be further addressed. In line with precision medicine being the next frontier in clinical medicine, the meeting will also highlight new advances in the pharmacogenomics, proteomics, and metabolomics of the RAAS in human diseases. Preceding the GRC, we will have the 2022 Gordon Research Seminar (GRS), a special forum for graduate students, postdoctoral fellows, early career researchers and other junior scientists to present and exchange new data and cutting-edge ideas. The 2022 GRS will focus on recent advances in RAAS studies beyond the classical paradigms, including new functions of receptors from this system and providing trainees with an enhanced understanding of current tools to aid their research, and cover a wide range of topics including the immune system, sex differences and aging. Additionally, the mentorship sessions will address the interplay between academia and industry and discuss approaches to translate scientific discoveries to the clinic and how to optimize impact. The aims are aligned with the NHLBI, NIDDK and NIAID missions and initiative and the scientific themes that will be covered are of direct relevance to these institutes. NIH funds requested will help attract young investigators and trainees, including from underrepresented groups with limited opportunities to joint top national and international experts in the RAAS for networking among researchers, clinicians, young investigators and trainees.

项目摘要 肾素血管紧张素醛固酮系统（RAAS）是心血管（CV）功能的关键调节剂 电解质平衡和稳态，它影响了许多系统，包括肾脏，神经内分泌和 免疫系统。 RAAS的扰动触发了一系列事件，包括产生血管活性 介质，氧化应激，炎症反应和组织重塑，从而有助于最终器官 病理和疾病。在2022年的ANG GRC中，我们将讨论最新的最前沿发现 领域并分享有关简历系统以外的新领域的见解，例如RAAS在 脂肪生物学，骨髓调节，肝功能，神经认知和免疫反应。这 会议将重点介绍从发现科学到临床影响的RAA的最新进展。亮点 2022年将庆祝ACE2的22周年。 ACE2是一种多功能蛋白，不是 仅通过分别从Ang II和Ang I生成Ang-（1-7）和Ang-（1-9）来保护CV保护性，但它也是 组织通过充当SARS-COV-2的受体，这是当前全球的病因学药物的受体 2019冠状病毒病大流行。 ACE2作为RAAS保护臂中的钥匙酶的谜团将是 强调。 ACE2作为COVID-19中的主要介体和潜在的治疗靶标的作用将是有争议的 以及关于共同19感染和人群长期结局进展的争议 用ACE抑制剂和/或血管紧张素受体阻滞剂处理。 2022 GRC ANG将进一步特征 新的主题，包括在生命过程中的调节和RAAS变化中的性别差异（胎儿） 编程，肾脏发展和衰老）将进一步解决。与精度药物一致 临床医学领域的下一个领域，会议还将重点介绍药物基因组学的新进步， 蛋白质组学和人类疾病中的RAA的代谢组学。在GRC之前，我们将拥有2022 戈登研究研讨会（GRS），一个专业的研究生论坛，博士后研究员，早期职业 研究人员和其他初级科学家介绍和交换新的数据和尖端思想。 2022年 GRS将重点介绍超出经典范式的RAAS研究的最新进展，包括新功能 来自该系统的受体，并为受训者提供对当前工具的增强的了解 他们的研究，并涵盖了包括免疫系统，性别差异和衰老在内的广泛主题。 此外，指导会议将解决学术界与行业之间的相互作用，并讨论 将科学发现转化为诊所的方法以及如何优化影响。目标是对齐的 有了NHLBI，NIDDK和NIAID任务和主动权以及将要涵盖的科学主题 与这些机构的直接相关性。 NIH要求的资金将有助于吸引年轻的调查员和受训者， 包括代表性不足的团体，机会有限 在研究人员，临床医生，年轻研究人员和学员之间进行网络的RAAS。